bone-modifying agents

Research Reports

Bone-Modifying Agent Utilization: An Analysis in Patients With Metastatic Cancer and Bone Involvement at an NCI-Designated Cancer Center

04/12/2023

Julie Gralow , MD, FACP, FASCO;

Micah Tratt ;

Keith D. Eaton , MD, PhD;

Poorni M. Manohar , MD;

Kyle E. Bastys ;

Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.

Manohar et al investigate the...

04/12/2023

Journal of Clinical Pathways

Research in Review

Less-Frequent Dosing Noninferior to Standard Dosing of Bone-Modifying Agent for Breast Cancer

01/30/2017

JCP Editors

A less-frequent dosing schedule of a bone-modifying agent (BMA) for treatment of skeletal-related events related to metastatic breast cancer is noninferior to standard dosing, according to research published in JAMA...

A...

01/30/2017

Journal of Clinical Pathways